Human cystatin C (or cystatin 3, CST3), which is composed of 120 amino acid residues, belongs to the cystatins superfamilly that inactivates lysosomal cysteine proteinases. As a strongly cationic and low-molecular weight (13.4 kDa) protein, it is almost freely filtered across the glomerular membrane, and is mainly used as a biomarker of kidney function. A growing body of evidence suggests that cystatin C is a more reliable biomarker of glomerular filtration rate than creatinine [1-3].
In addition to kidney disease, altered serum levels of cystatin C are associated with several types of cardiovascular disease, including myocardial infarction, stroke, heart failure, peripheral arterial disease and metabolic syndrome [4-7]. It also seems to play a role in brain disorders involving amyloid, such as Alzheimer's disease [8, 9]. Furthermore, Cystatin C has also been investigated as a prognostic marker in several forms of cancer [10-12].

Click Here

Rabbit crude IgG was purified by protein-G column.

Recombinant full-length human Cystatin C expressed in E.coli.

The antibody detects human Cystatin C

Solution in PBS.

Standard ELISA test, Western blot, Immunoturbidimetric assay

BCA to determine quantity of the antibody

Store at –20°C. For long-term storage, aliquot and freeze at -70°C. Avoid repeated freeze/defrost cycles.

[1] Stevens LA, Coresh J, Schmid CH, et al. (2008) Am J Kidney Dis. 51:395–406.
[2] Dharnidharka VR, Kwon C, Stevens G. (2002) Am. J. Kidney Dis. 40 (2): 221–6.
[3] Hermida J, Tutor JC. (2006) Ther Drug Monit. 28 (3): 326–31.
[4] Zethelius B, Berglund L, Sundström J, et al. (2008) N. Engl. J. Med. 358 (20): 2107–16.
[5] Ix JH, Shlipak MG, Chertow GM, Whooley MA. (2007) Circulation 115 (2): 173–9.
[6] Deo R, Fyr CL, Fried LF, et al. (January 2008) Am. Heart J. 155 (1): 62–8. 
[7] Servais A, Giral P, Bernard M, et al. (2008) Am. J. Med. 121 (5): 426–32.
[8]Mi W, Pawlik M, Sastre M, et al. (2007) Nat. Genet. 39 (12): 1440–2.
[9] Kaeser SA, Herzig MC, Coomaraswamy J, et al. (2007) Nat. Genet. 39 (12): 1437–9.
[10] Zurdel J, Finckh U, Menzer G, et al. (2002) Br J Ophthalmol 86 (2): 214–9.
[11] Strojan P, Oblak I, Svetic B, et al. (2004) Br. J. Cancer 90 (10): 1961–8. 
[12] Kos J, Krasovec M, Cimerman N, et al. (2000) Clin. Cancer Res. 6 (2): 505–11.